Compare ASAN & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASAN | BLLN |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 2020 | N/A |
| Metric | ASAN | BLLN |
|---|---|---|
| Price | $6.97 | $76.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 7 |
| Target Price | $12.46 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 6.6M | 372.4K |
| Earning Date | 06-02-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $790,806,000.00 | N/A |
| Revenue This Year | $10.19 | $46.29 |
| Revenue Next Year | $7.91 | $30.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.25 | N/A |
| 52 Week Low | $5.38 | $61.96 |
| 52 Week High | $19.00 | $138.70 |
| Indicator | ASAN | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 60.71 | 45.20 |
| Support Level | $6.51 | $64.99 |
| Resistance Level | $8.20 | $83.20 |
| Average True Range (ATR) | 0.41 | 6.09 |
| MACD | 0.14 | -1.22 |
| Stochastic Oscillator | 93.64 | 23.02 |
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.